|Articles|April 25, 2007

images

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe

Related Content

FDA approves capivasertib plus abiraterone and prednisone for PTEN-deficient mHSPC

ByHannah Clarke

June 12th 2026

FDA approves adjuvant belzutifan with pembrolizumab for ccRCC

ByHannah Clarke

June 12th 2026

The UroOnc Minute: Variant Histologies in Bladder Cancer, With Carissa Chu, MD

ByAdam B. Weiner, MD,Carissa Chu, MD

June 12th 2026

Benjamin Lowentritt, MD, reviews real-world testosterone recovery data with relugolix

ByBenjamin H. Lowentritt, MD, FACS

June 11th 2026

SABR demonstrates safety and local control in primary renal cell carcinoma

ByHannah Clarke

June 11th 2026

Latest CME

Video

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

Multimedia

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Video

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

images

Related Content

FDA approves capivasertib plus abiraterone and prednisone for PTEN-deficient mHSPC

FDA approves adjuvant belzutifan with pembrolizumab for ccRCC

The UroOnc Minute: Variant Histologies in Bladder Cancer, With Carissa Chu, MD

Benjamin Lowentritt, MD, reviews real-world testosterone recovery data with relugolix

SABR demonstrates safety and local control in primary renal cell carcinoma

Latest CME

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Radioligand Therapy 101: The Science Behind the Strategy

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Trending on Urology Times

Clinical Application of MMAI Score in Patients with Prostate Cancer

FDA approves capivasertib plus abiraterone and prednisone for PTEN-deficient mHSPC

FDA approves adjuvant belzutifan with pembrolizumab for ccRCC

Benjamin Lowentritt, MD, reviews real-world testosterone recovery data with relugolix

Kevin Zorn, MD, on selecting among different MIST options for BPH